- Home
- NGNE vs GCL Comparison
NGNE vs GCL Comparison
Compare NGNE & GCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- GCL
- Stock Information
- Founded
- NGNE 2003
- GCL 2011
- Country
- NGNE United States
- GCL Singapore
- Employees
- NGNE N/A
- GCL N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- GCL
- Sector
- NGNE Health Care
- GCL
- Exchange
- NGNE Nasdaq
- GCL NYSE
- Market Cap
- NGNE 325.3M
- GCL 314.4M
- IPO Year
- NGNE N/A
- GCL N/A
- Fundamental
- Price
- NGNE $22.72
- GCL $4.08
- Analyst Decision
- NGNE Strong Buy
- GCL
- Analyst Count
- NGNE 7
- GCL 0
- Target Price
- NGNE $41.86
- GCL N/A
- AVG Volume (30 Days)
- NGNE 216.3K
- GCL 80.9K
- Earning Date
- NGNE 08-08-2025
- GCL 01-01-0001
- Dividend Yield
- NGNE N/A
- GCL N/A
- EPS Growth
- NGNE N/A
- GCL N/A
- EPS
- NGNE N/A
- GCL N/A
- Revenue
- NGNE $925,000.00
- GCL $112,351,837.00
- Revenue This Year
- NGNE N/A
- GCL N/A
- Revenue Next Year
- NGNE N/A
- GCL N/A
- P/E Ratio
- NGNE N/A
- GCL N/A
- Revenue Growth
- NGNE N/A
- GCL 25.23
- 52 Week Low
- NGNE $6.88
- GCL $1.76
- 52 Week High
- NGNE $74.49
- GCL $9.89
- Technical
- Relative Strength Index (RSI)
- NGNE 60.64
- GCL N/A
- Support Level
- NGNE $20.80
- GCL N/A
- Resistance Level
- NGNE $23.88
- GCL N/A
- Average True Range (ATR)
- NGNE 1.44
- GCL 0.00
- MACD
- NGNE 0.09
- GCL 0.00
- Stochastic Oscillator
- NGNE 72.83
- GCL 0.00
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About GCL GCL GLOBAL HOLDINGS LTD
GCL Global Holdings Ltd is a provider of games and entertainment content based in Asia. The company unites people through games and entertainment experiences, enabling creators to deliver engaging content and fun gameplay experiences to the gaming communities across the globe, with a strategic focus on the rapidly expanding Asian gaming market. Its mission is to bridge cultures and audiences by introducing Asian-developed IP to a multinational audience across consoles, PCs and streaming platforms.